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Immune responseActivation of interferon regulatory factors (IRFs) 3 and 7 is essential for the induction of Type I interferons
(IFN) and innate antiviral responses, and herpesviruses have evolved mechanisms to evade such responses.
We previously reported that Epstein–Barr virus BZLF1, an immediate-early (IE) protein, inhibits the function
of IRF7, but the role of BRLF1, the other IE transactivator, in IRF regulation has not been examined. We now
show that BRLF1 expression decreased induction of IFN-β, and reduced expression of IRF3 and IRF7; effects
were dependent on N- and C-terminal regions of BRLF1 and its nuclear localization signal. Endogenous IRF3
and IRF7 RNA and protein levels were also decreased during cytolytic EBV infection. Finally, production of
IFN-β was decreased during lytic EBV infection and was associated with increased susceptibility to
superinfection with Sendai virus. These data suggest a new role for BRLF1 with the ability to evade host
innate immune responses.ncer Center, University of North
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Interferon (IFN) regulatory factors (IRFs) are a family of transcrip-
tion factors that play a critical role in the regulation of IFN-stimulated
genes (ISGs) as well as the induction of the Type I IFNs, including IFN-
α and IFN-β. The human IRF family, which consists of 9 members
(IRF1–9), is deﬁned by a highly conserved amino-terminal DNA-
binding domain characterized by a ﬁve-tryptophan residue repeat
(Eason et al., 1999) that allows the IRFs to bind, as homodimers or
heterodimers, to consensus GAA and AANNNGAAmotifs found in IFN-
stimulated response elements (ISREs), including promoters of the
Type I IFNs and ISGs (Paun and Pitha, 2007). This interaction mediates
how IRFs exert critical effects on ISG expression, cellular growth,
cellular differentiation, and innate immune responses (Barnes et al.,
2002; Nguyen et al., 1997; Paun and Pitha, 2007; Tamura et al., 2008).
Of all themembers of the IRF family, IRF3 and IRF7 are considered to
be the key regulators of the expression of Type I IFNs (Honda et al., 2006,2005; Honda and Taniguchi, 2006; Paun and Pitha, 2007; Sakaguchi et
al., 2003; Zhang and Pagano, 1997, 2002). While IRF3 is responsible for
the early phase of Type I IFN induction, IRF7 is nowunderstood to be the
master regulator of all Type I IFN-dependent responses (Honda et al.,
2006, 2005), and together they are critical elements in the activation of
host innate immune responses, particularly in response to infection by
different pathogens, including viruses. Virus-infected cells produce a
mixture of Type I IFNs, but ﬁbroblasts and epithelial cells synthesize
predominantly IFN-β, whereas leukocytes, macrophages, and dendritic
cells mainly express IFN-α (Malmgaard, 2004). Together, the produc-
tion of both IFN-α and IFN-β has important immune-modulatory
consequences, speciﬁcally through enhancing antigen presentation in
virally infected cells leading to their destruction (Malmgaard, 2004) as
well as through regulation of cytokines released by the infected cells
(Abele andTampe, 2004; Luft et al., 1998;Malmgaard, 2004). In addition
to the antiviral effects of the Type I IFNs, ISGs are also important for host
innate immune responses through their ability to inhibit viral
replication through degradation of RNA and inhibition of protein
translation (Sen and Sarkar, 2007).
The ability of IRF3 and IRF7 to regulate the expression of both Type
I IFNs and ISGs points to the importance of these transcription factors
in controlling viral infection and virus replication. Viruses, including
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circumvent the activation of IRF3 and IRF7 and block innate responses.
For example, binding and entry of herpesviruses into cells promotes
activation of IRF3 and IRF7 (Grandvaux et al., 2002; Li et al., 2004;
Means et al., 2002; Miller et al., 2002; Pollara et al., 2004). However,
despite this initial activation of cellular antiviral responses accumu-
lation of IFNs and ISG transcripts is inhibited following viral
replication (Grandvaux et al., 2002; Li et al., 2004; Means et al.,
2002; Miller et al., 2002; Pollara et al., 2004).
Speciﬁc examples can be found in each Herpesviridae subfamily.
For the α-herpesviruses, the immediate-early protein, ICP0, of bovine
herpesvirus I and herpes simplex virus inhibits the activity of IRF3 by
recruiting activated IRF3 and inducing its degradation (Melroe et al.,
2004, 2007; Saira et al., 2007). ICP0 also inhibits IRF7 transactivation
activity (Saira et al., 2007) as well as inactivates the Jak/Stat signaling
pathway, thereby impeding the expression of the Type I IFNs (Eidson
et al., 2002; Harle et al., 2002; Lin et al., 2004; Melroe et al., 2004,
2007; Pollara et al., 2004; Saira et al., 2009). The β-herpesvirus human
cytomegalovirus (HCMV) encodes a protein, pp65, that subverts the
activation of IRF3 by inhibiting its nuclear accumulation and
regulating innate immune responses (Abate et al., 2004). The IE
protein 1 of the related β-herpesvirus HHV-6 also inhibits the nuclear
localization of IRF3 leading to decreased IFN-β production (Jaworska
et al., 2007). For the γ-herpesviruses, human herpesvirus-8 (Kaposi's
sarcoma herpesvirus; KSHV) and the related rhesus rhadinovirus
encode a cluster of IRF homologous genes, called viral IRFs (vIRFs),
which cannot bind to ISREs but suppress expression of the Type I IFNs
by forming heterodimers with cellular IRFs and repressing their ability
to transactivate promoters (Barnes et al., 2002). We have shown that
Epstein–Barr virus (EBV) IE protein Zta (BZLF1) physically interacts
with IRF7, inhibiting its ability to activate the IFN-α, IFN-β, and Tap2
promoters (Hahn et al., 2005). The EBV tegument protein LF2 also
interacts with IRF7, inhibiting its ability to bind to and activate the
IFN-α promoter (Wu et al., 2009). In addition, EBV BGLF4, the viral PK,
interacts with IRF3 and reduces the amount of active IRF3 recruited to
ISREs and thus inhibits induction of the Type I IFNs (Wang et al.,
2009a). These ﬁndings led us to ask whether other EBV proteinsmight
regulate the activity of IRFs and inhibit innate immune responses.
Infection with EBV produces both lytic and latent infections. The
initiation of the lytic cycle, either via primary infection or following
reactivation of viral replication from the latent state, is controlled by the
IE proteins BZLF1 (Zta) and BRLF1 (Rta). EBV Rta is a 605-amino-acid
(aa) proteinwith noknown cellular homologs. TheN-terminal region of
Rta contains a DNA-binding domain (aa 1–280) that coincides with a
dimerization domain (aa 1–232) (Manet et al., 1993, 1991). The mid-
region of Rta contains the nuclear localization sequence (NLS), which is
responsible for the localization of Rta in the nucleus (Hsu et al., 2005).
The C-terminal region of Rta contains the transcriptional activation
domain that interacts with TATA-binding protein and TFIID (Manet et
al., 1993, 1991). While EBV Rta mainly functions as a transcriptional
inducer of early and late viral genes, it also interactswith several cellular
proteins and affects the activities of host cells to facilitate viral
replication (Adamson et al., 2000; Darr et al., 2001; Li et al., 2004). To
date, no known immunomodulatory function has been uncovered for
Rta, and knowledge of the mechanisms by which EBV escapes innate
immune responses is still incomplete.
Here we show that EBV Rta can downregulate the transcription of
IRF3 and IRF7 resulting in decreased protein expression and thereby
modulate Type I IFN responses to virus infection. Endogenous levels of
these IRFs, but not IRF5, are reduced during reactivation of the viral
lytic cycle in EBV-infected cells. Finally, endogenous levels of Type I
IFN, speciﬁcally IFN-β, are decreased following EBV reactivation and
coincide with increased susceptibility of the EBV-infected cells to
superinfection with Sendai virus. These ﬁndings suggest that EBV can
avert suppression of viral replication by Type I IFNs by down-
regulation of IRF3 and IRF7.Results
Rta negatively regulates IFN-β promoter activity
IFN promoter-reporter activity is inhibited during γ-herpesvirus lytic
infection (Hahnet al., 2005;Manet et al., 1993).Wehave reported that the
EBV IE transactivator Zta inhibits IFNpromoter activity (Hahnet al., 2005),
and others have shown KSHV ORF50/Rta downregulates IFN activity
(Manet et al., 1993). Therefore, we investigated whether EBV Rta could
inhibit IFN responses by similar or different mechanisms. To determine
whether IFN-β expression is downregulated by Rta, luciferase activity
from the IFN-β promoter-reporter construct, an established target of IRFs
(Lin et al., 2000; Yang et al., 2004), was assayed in 293 T cells.
IFN-β reporter construct was transfected into 293 T cells with control
vector or plasmid encoding EBV Rta. Following transfection, cells were
infectedwithSendaivirus,which inducesa robustantiviral response. IFN-β
promoter activity wasmeasured by relative luciferase activity, normalized
to renilla-luciferase expression. Upon Sendai virus infection, transfected
cells showed a 46-fold increase in relative IFN-β promoter activity
(Fig. 1A). Co-expression of EBV Rta strongly suppressed this increased
promoter activity, returning it to basal levels and indicating that EBV Rta
protein strongly inhibits Sendai virus-induced IFN-β promoter activity.
To examine the biological relevance of these ﬁndings more
directly, endogenous IFN-β RNA levels were also examined
(Fig. 1B). 293 T cells were transfected with control vector or EBV
Rta and mock- or Sendai virus-infected 16 h after transfection. Semi-
quantitative RT-PCR was performed on RNA harvested 24 h after
transfection (8 h after infection). Results revealed a trend similar to
that observed with the reporter assays in which Sendai virus infection
strongly induced the production of IFN-β RNA, and EBV Rta expression
greatly inhibited this response. These results suggest that EBV Rta is
capable of regulating the activation of the IFN-β promoter and in turn
the production of IFN-β, thus regulating Type I IFN responses.
Because IRF3 and IRF7 play central roles in the production of Type I
IFN, including IFN-β, during virus infection (Honda et al., 2006, 2005;
Honda and Taniguchi, 2006; Paun and Pitha, 2007; Sakaguchi et al.,
2003; Zhang and Pagano, 1997, 2002), we next examined whether EBV
Rta affected transcriptional activities of IRF3 and IRF7 by IFN-β reporter
assays, in which IRF3 or IRF7 were co-expressed with the viral protein.
The results showed that overexpression of IRF3 and IRF7 signiﬁcantly
(Pb0.05) increased transactivation of the IFN-β promoter (Fig. 1C and
D). EBV Rta expression abrogated the increased transcriptional activity
of IRF3 and IRF7 (Fig. 1B and C) but did not affect basal IFN-β promoter
activity. Thesedata suggest that EBVRta can suppress inductionof IFN-β
by down-regulating the activities of IRF3 and IRF7.
EBV Rta negatively regulates levels of IRF3 and IRF7 proteins
To decipher how EBV Rta suppressed the transcriptional activity of
IRF3 and IRF7, we ﬁrst examined whether it altered their expression
along with that of IRF5, an IRF family member involved in signal
transduction events triggered by virus infection that activate Toll-like
receptors (Barnes et al., 2002;Malmgaard, 2004; Takaoka et al., 2005).
293 T cells were transfectedwith Flag-tagged IRFs and RTA expression
plasmids, and IRF and Rta expression was analyzed 24 h later. High
levels of Flag-tagged IRF3, IRF5, and IRF7 were detected (Fig. 2A). Co-
expression of EBV Rta consistently coincided with decreased
expression levels of IRF3 and IRF7 while IRF5 levels were not altered
(Fig. 2A). Thus, EBV Rta selectively down-regulates the expression of
IRF3 and IRF7, the main regulators of the Type I IFNs.
Rta downregulates IRF3 and IRF7 expression in the cytoplasm and
nucleus independent of its localization
The phosphorylation of the IRFs, including IRF3 and IRF7, and their
subsequent nuclear translocation are important steps in their
Fig. 1. EBV Rta regulates IFN-β promoter activity. (A) 293 T cells were transfected with EBV Rta or vector control along with IFN-β reporter plasmid and Renilla luciferase plasmid.
Cells were mock-infected or infected with Sendai virus (50 HA units/ml) 16 h post-transfection. Eight hours later (24 h post-transfection), cells were harvested for ﬁreﬂy luciferase
assays and normalized to Renilla luciferase expression. (B) 293 T cells were transfected with EBV Rta or vector control and Sendai virus infected 16 h post-transfection. 24 h post-
transfection, cells were collected and RNA harvested for semi-quantitative RT-PCR to examine IFN-β and GAPDH expression. 293 T cells were transfected with the vector control or
(C) IRF3 or (D) IRF7 in the presence or absence of EBV Rta or the vector control and luciferase assays were performed 24 h post-transfection. Data are shown as the fold change
(relative to vector control) ± standard deviation of experiments performed in triplicate.
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We next determined if EBV Rta affects the activation of IRF3 and IRF7
in addition to regulating their expression levels. Cytoplasmic and
nuclear extracts were collected 24 h after transfection and analyzed
by Western blot analyses. IRF3 and IRF7 were detected in both
cytoplasmic and nuclear extracts (Fig. 2B), suggesting that they are
activated by phosphorylation resulting in their nuclear translocation.
Co-expression of EBV Rta resulted in reduced expression of IRF3 andFig. 2. EBV Rta negatively regulates IRF3 and IRF7 protein expression but does not alter
IRF5 expression. 293 T cells were transfected with Flag-IRF3, Flag-IRF5, Flag-IRF7, and/
or Flag-EBV Rta as indicated. (A) 48 h post-transfection whole cell lysates were
collected and Western blot analyses performed examining Flag expression/exogenous
protein expression. B) 48 h post-transfection, cytoplasmic extracts and nuclear extracts
were collected and Western blot analyses performed examining Flag expression in the
two extracts. Tubulin and lamin were used as loading controls.IRF7 in both the cytoplasmic and nuclear extracts (Fig. 2B), but the
proteins were still detected in both extracts. These data conﬁrm that
the expression of EBV Rta inhibits the expression of IRF3 and IRF7 and
suggests that Rta does not affect the activation, phosphorylation, and
nuclear translocation of these IRFs.All three EBV Rta functional domains are required for its ability to
regulate IRF3 and IRF7 expression
To examine the mechanism by which EBV Rta regulates the
expression of IRF3 and IRF7, the contributions of the different
functional domains of Rta thatmediate its function as a transcriptional
activator were examined. Three main Rta domains are the amino
terminus, which contains a DNA-binding domain (aa 1 to 280), a
dimerization domain (aa 1 to 232), and a transcriptional activation
domain in the carboxy-terminus which contains a nuclear localization
signal (Manet et al., 1993, 1991). EBV Rta (pGFP-Rta wt (GFP-tagged
Rta (aa 1–605)), Rta domain mutants (pGFP-Rta ΔNLS (mutation of
the NLS); pGFP-Rta ΔN (aa 100–605); pGFP-Rta ΔC (aa 1–441)), or
empty vector were co-expressed with ﬂagged-tagged IRF3 or IRF7.
GFP-Rta wt, GFP-Rta ΔN, and GFP-Rta ΔC localized to the nucleus,
while GFP-Rta ΔNLS was only detected in cytoplasm (data not
shown), conﬁrming that the NLS is required for the nuclear
translocation of Rta. IRF3, IRF7, and all forms of Rta were expressed
at expected molecular sizes (Fig. 3). High levels of Flag-tagged IRF3
and IRF7 were detectable when co-expressed with empty GFP vector,
but levels were signiﬁcantly down-regulated when co-expressed with
GFP-Rta. Deletion of the N- or C-termini or mutation in the NLS
sequence of Rta completely abrogated its ability to alter expression of
IRF3 and IRF7. Together, these data demonstrate that both the DNA-
binding and dimerization domains of the N-terminus and the C-
terminal transactivation domain are required for EBV Rta to regulate
expression of IRF3 and IRF7. In addition, the ﬁnding that the NLS is
Fig. 3. All classiﬁed EBV Rta function domains are required for the regulation of IRF3 and
IRF7 expression. 293 T cells were transfected with Flag-IRF3, Flag-IRF7, and GFP-EBV
Rta or select GFP-EBV Rta mutants as indicated. 48 h post-transfection whole cell
lysates were collected and Western blot analyses performed examining Flag and GFP
expression. Tubulin was used as a loading control.
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may regulate their expression at the transcriptional level.Rta expression reduces endogenous RNA levels of IRF3 and IRF7 but not
IRF5
Rta is a known transcription factor (Ragoczy et al., 1998; Ragoczy
and Miller, 1999), so we tested whether it could regulate the
expression of the IRFs at the transcriptional level by assay of
endogenous levels of IRF RNAs by semi-quantitative RT-PCR. 293 T
cells, transfected with EBV Rta or vector control, were stimulated with
Type I IFN, RNA extracted and levels of IRF3, IRF5, IRF7, and actin,
which was used as a loading control, were measured. Levels of IRF3,
IRF5, IRF7 RNA were readily detectable (Fig. 4A). Over-expression of
EBV Rta resulted in reduced IRF3 and IRF7 RNA levels while IRF5 RNA
levels remained unchanged (Fig. 4A).Fig. 4. EBV Rta reduces endogenous RNA levels of IRF3 and IRF7. 293 T cells were
transfected with vector control or EBV Rta as indicated. 14 h post-transfection, cells
were (A) stimulated with 500U/ml of Type I IFN or (B) infected with Sendai virus
(50 HA units/ml). Cells were collected and RNA harvested 24 h post-transfection. Semi-
quantitative RT-PCR was performed to detect expression of IRF3, IRF5, and IRF7. Actin
and GAPDH were used as loading controls.To conﬁrm these results, 293 T cells were also transfected with EBV
Rta or vector control and infected with Sendai virus (50 HA units/ml).
RNA was extracted and semi-quantitative RT-PCR performed to
examine the expression of endogenous levels of IRF3, IRF5, and IRF7
(Fig. 4B). The data showed that Sendai virus slightly increased
expression of these two IRFs and Rta expression reduced IRF3 and
IRF7 RNA levels. IRF5 levels remained the same. Together, these results
demonstrate that EBV Rta selectively regulates the expression of IRF3
and IRF7 at the transcriptional levels, which in turn accounts for the
decreased protein levels observed (Figs. 2 and 3).
Endogenous IRF3 and IRF7 RNA and protein levels are diminished during
viral reactivation
Finally, we examined the expression of IRF3 and IRF7 in the viral
lytic cycle. Akata cells are latently EBV-infected Burkitt's lymphoma
cells in which viral reactivation can be induced by cross-linking
surface B-cell receptors with IgG (Gershburg et al., 2004; Takada and
Ono, 1989; Zacny et al., 1999). Cells were collected 0, 24, and 48 h
after induction and divided so that RNA could be extracted for RT-PCR
and protein analyzed by Western blot analyses.
IRF3, IRF5 and IRF7 RNAwere all readily detectable in Akata cells at
the time of induction (Fig. 5A). 24 and 48 h later, RNA levels for IRF3
and IRF7 were decreased but IRF5 levels remained unchanged. IRF3
and IRF7, but not IRF5, protein levels decreased in a similar fashion
(Fig. 5B). As a control for viral reactivation, we also examined the
expression of Rta and EA-D, an EBV early gene (Fig. 5B). Densitometry
of relative IRF RNA and protein levels normalized to relative GAPDH
RNA and protein levels conﬁrmed the trend observed in IRF3 and IRF7
expression. These data demonstrate that EBV Rta inhibits the
expression of IRF3 and IRF7 at the transcriptional level resulting in
decreased protein expression.
The biological relevance of these data was also investigated by
examining the endogenous expression of IFN-β following Akata cell
induction as well as by examining the susceptibility of uninduced and
induced Akata cells to Sendai virus superinfection. First, semi-
quantitative RT-PCR was performed to examine RNA levels of IFN-β in
Akata cells at 0, 24, and 48 h post-induction (Fig. 6A). Densitometry of
relative IFN-β RNA levels normalized to relative GAPDH RNA levels
showed that there is a signiﬁcant (Pb0.05) decrease in IFN-β expression
by 48 h post-induction, which coincides with decreased IRF3 and IRF7
expression. Second, Akata cells were induced or left uninduced for 24 h
and then infected with Sendai virus (50 HA units/ml) for 24 h. Cell
supernatant ﬂuids were collected and used to quantitate Sendai virus
replication by plaque assays on LLC-MK2 cells. The data showed that
induced Akata cells were signiﬁcantly (Pb0.05) more susceptible to
Sendai virus superinfectionwhen comparedwith uninduced Akata cells
(Fig. 6B). Speciﬁcally, Sendai virus reached titers 13-fold greater in
induced Akata cells compared to uninduced cells. Together, these data
suggest that EBV Rta contributes to immune evasion and inhibition of
Type I IFN responses during lytic infection through regulation of IRF3
and IRF7 expression.
Discussion
Protection from consequences of viral infection depends on innate
immune responses. To evade such responses, herpesviruses have
evolved mechanisms by which they inhibit the central activators of
Type I IFN responses, IRF3 and IRF7 (Abate et al., 2004; Barnes et al.,
2002; Eidson et al., 2002; Hahn et al., 2005; Harle et al., 2002;
Jaworska et al., 2007; Lin et al., 2004; Pollara et al., 2004; Saira et al.,
2009; Wu et al., 2009). Relatively little has been reported on how EBV
performs such maneuvers. Recently three EBV products expressed at
early stages of productive viral infection, Zta, LF2, and BGLF4, have
been reported to interact with IRF7 and inhibit the induction of IFN-β
(Hahn et al., 2005;Wu et al., 2009). Here we have shown that EBV Rta,
Fig. 5. Endogenous IRF3 and IRF7 RNA and protein expression is reduced during EBV lytic infection. Viral reactivation was performed in Akata cells where the cells were incubated
with F(AB')2 fragment to human IgG for 0 h (0 h), 24 h (24 h), or 48 h (48 h). (A) Total RNA was harvested and semi-quantitative RT-PCR performed examining IRF3, IRF5, IRF7, and
Rta RNA expression. (B) Whole cell lysates were collected and Western blot analyses performed examining IRF3, IRF5, IRF7, Rta, and EA-D protein expression. Densitometry was
performed in which relative RNA or protein expression was normalized to relative GAPDH expression. Data are shown as fold change (relative to 0 h post-induction) ± standard
deviation of experiments performed in triplicate.
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and IRF7 by a different mechanism. Speciﬁcally, EBV Rta suppressed
IFN-β promoter activity and RNA levels induced by Sendai virus by
reducing levels of IRF3 and IRF7 RNA and protein, which are ordinarily
expressed during viral infection. Suppression of these IRFs wasFig. 6. Endogenous IFN-β RNA levels decrease during EBV lytic infection and coincide
with increased susceptibility to Sendai virus infection. Viral reactivation was induced in
Akata cells as in Fig. 5. (A) Total RNA was harvested and semi-quantitative RT-PCR
performed to detect IFN-β and GAPDH RNA at 0, 24, and 48 h post-induction.
Densitometry was performed where relative IFN-β levels were normalized to relative
GAPDH levels. Data are shown as the fold change (relative to 0 h post-induction) ±
standard deviation of experiments performed in triplicate. (B) 24 h after induction (or
mock-induction), Akata cells were infected with Sendai virus (50 HA units/ml). 24 h
after infection, supernatant ﬂuids were collected for plaque assays on LLC-MK2 cells.
Viral titers were determined and data are shown as PFU/ml ± standard deviation of
experiments performed in triplicate.selective in that IRF5 was not affected. In addition, endogenous IRF3
and IRF7 RNA and protein levels were reduced during lytic EBV
replication, and coincide with decreased levels of IFN-β RNA and
increased susceptibility of the EBV-infected cells to superinfection
with Sendai virus.
Our ﬁndings also demonstrate that the mechanism whereby EBV
Rta causes evasion of Type I IFNs is quite different from that used by its
KSHV homolog (KSHV Rta, ORF50). Speciﬁcally, EBV Rta does not
inﬂuence the activation and nuclear translocation of the IRFs (Fig. 2B),
whereas KSHV Rta inhibits these events (Yu et al., 2005). Further-
more, KSHV Rta functioned as an ubiquitin E3 ligase for IRF7 resulting
in its ubiquitination and proteasome-mediated degradation (Yu et al.,
2005). However, we could not detect EBV Rta E3 ligase activity with
the substrates tested (Supplemental Fig. 1).
We deﬁne a novel mechanism by which EBV Rta contributes to
immune evasion. Rta has been shown to bind directly and indirectly to
several promoters (Adamson et al., 2000; Darr et al., 2001; Hsu et al.,
2005; Kenney et al., 1989; Quinlivan et al., 1993), and we show that
expression of Rta resulted in decreased endogenous IRF3 and IRF7 RNA
and protein levels, but not IRF5 levels. Because Rta also inhibited
overexpression of IRF3 and IRF7, it is possible that Rta affects
expression by binding to GC-rich regions of these genes or by affecting
RNA elongation. However, this mechanism has not been reported for
Rta or any IRFs.
Not only herpesviruses but other viruses can suppress innate
immune responses by inhibiting the activity of IRF3 and IRF7 (Abate
et al., 2004; Barnes et al., 2002, 2004; Eidson et al., 2002; Hahn et al.,
2005; Harle et al., 2002; Lin et al., 2004; Pollara et al., 2004; Saira et al.,
2009; Wang et al., 2009a; Wu et al., 2009). Human papillomavirus and
hepatitis B virus encode proteins that prevent the activation of IRF3
(Wang et al., 2009b) or the expression of IRF7 (Xu et al., in press),
respectively, resulting in suppression of the Type I IFNs. Other quite
different viruses, including the RNA viruses Ebola, hepatitis C, and
rotavirus all are united by encoding proteins that inhibit the activation
of IRF3 (Baril et al., 2009; Basler et al., 2003; Foy et al., 2003; Hartman
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likely that most viruses have mechanisms by which they evade the
activation of the Type I IFNs to allowvirus replication to occur. Apossible
common link between DNA and RNA virus infection and regulation of
the innate immune responses is the ability of the virus to regulate Toll-
like receptor (TLR) signal transduction events (Schroder and Bowie,
2007; Severa and Fitzgerald, 2007).
The data presented here disclose how EBV Rta affects IRF3 and IRF7
expression and induction of IFN promoters thus regulating expression
of the Type I IFNs; similar effects have also been observed with other
members of the IRF family. IRF1 is involved in antiviral immune
responses mediated by IFN-γ (Paun and Pitha, 2007), and while it
does not have a role in virus stimulation of the Type I IFNs, it binds to a
transcription enhancer complex in the IFN-β promoter region
(Thanos and Maniatis, 1995). IRF2 can also bind to this complex and
regulate IFN-β expression (Paun and Pitha, 2007). IRF9 has distinct
antiviral effects in that it binds STAT1/2 heterodimers forming
another complex, IFN-stimulated growth factor 3, which binds ISREs
(Fu et al., 1992; Improta et al., 1994). Examination of the effect of EBV
Rta on the expression of IRF1, IRF2, and IRF9 revealed that EBV Rta
suppressed expression of IRF1 and IRF3, but not IRF9, at the
transcriptional level (Supplemental Fig. 2), resulting in decreased
protein expression and decreased transactivational activity (data not
shown). The basis for these selective effects on IRFs is unknown. EBV
Rta is well known for transactivational activity on EBV promoters
(Ragoczy et al., 1998; Ragoczy and Miller, 1999) as well as a cellular
promoter (Li et al., 2004), so it is possible that Rta directly exerts its
inhibitory effect on the promoters of IRF1, 2, 3, and 7 and does not
bind to the promoters of IRF5 and IRF9. Some support for this idea
comes from our data that the NLS, the DNA-binding and dimerization
domains, and the transactivating domain, which interacts with TATA-
binding protein and TFIID, are required for the observed Rta-mediated
response (Fig. 3). Together, these ﬁndings suggest a speciﬁc
mechanism by which EBV Rta regulates how select IRFs subvert the
activation of interferon responses.
We propose that EBV has multiple methods that target different
facets of the IFN response and suppresses its induction. For example,
Zta can counteract an inﬂammatory response via the inhibition of IRF7
activity but not through the down-regulation of IRF7 expression (Hahn
et al., 2005). Recently, a role for two EBV early proteins, LF2 and BGLF4,
in regulating the host IFN- mediated immune response based on their
ability to regulate the function of IRF7 and IRF3, has been uncovered
(Wang et al., 2009a; Wu et al., 2009). While EBV LF2 interacts with
IRF7, inhibiting its ability to bind to and activate the IFN-α promoter
(Wu et al., 2009), EBV BGLF1 interacts with IRF3 reducing the amount
of active IRF3 recruited to the ISREs (Wang et al., 2009a). Accordingly,
we propose that following viral reactivation, upon expression of the
EBV IE proteins Zta and Rta, Zta interacts with endogenous IRF7 and
possibly IRF3, inhibiting their activity. At the same time Rta decreases
the transcription of IRF3 and IRF7 resulting in decreased protein
expression. By the time the EBV early proteins, BGLF4 and LF2, are
expressed, only limited amounts of the IRFs are present in the cell, and
these viral proteins interact with and inhibit the remaining IRF3 and
IRF7. This multi-pronged mechanism ensures that the Type I IFN
response is inhibited and allows viral replication to occur. The role of
additional immediate-early (BHRF1), early, and late proteins in this
complex response remains to be examined, but it is likely that other
viral proteins contribute to the observed antiviral response.
Conclusion
We have shown here, for the ﬁrst time, that endogenous RNA and
protein levels of IRF3 and IRF7 are down-regulated during the course
of lytic EBV infection. The mechanism by which Rta regulates the
ability of the IRFs to induce IFN production (by transcriptional
regulation of IRF expression) is unique when compared with the wayother viral proteins regulate IFN responses, namely, by degrading the
IRFs or directly inhibiting their transactivational activity and thus
circumventing host immune responses. The fact that EBV invokes its
two principal IE lytic-cycle transactivators, Rta and Zta, and two early
lytic-cycle proteins in the suppression of IFN responses emphasizes
the biological importance of these events for successful viral
replication.
Materials and methods
Reagents and antibodies
N-carbobenzoxyl-L-leucinyl-L-norleucinal (MG132), mammalian
ubiquitin, rabbit ubiquitin-activating enzyme (E1), and recombinant
human UBCH6were purchased from Boston Biochem, Inc. (Cambridge,
MA). Protease-inhibitor cocktail was from Roche. The nuclear prepara-
tion kit was from Thermo Scientiﬁc (Rockford, IL). Antibodies against
IRF3, IRF5, IRF7, GAPDH, γ-tubulin, ubiquitin, GFP and lamin were
obtained from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). EBV Rta
antibodies were obtained from Argene (Varilhes, France). HA mAb
12CA5, FLAG mAb M2, Anti-FLAG afﬁnity beads and anti-HA afﬁnity
beads were from Sigma-Aldrich (St. Louis, MO). cIAP1 was expressed in
293 T cells and puriﬁed as previously described (Yang et al., 2000).
Plasmids and constructs
Flag-tagged full-length IRF3 and IRF5 cDNAswere inserted into the
mammalian expression vector pCMV-2. pCMV2-Flag-tagged IRF-7
expression plasmid was a gift from Dr. GeorgeMiller. pCI-GFP-Rta and
pCI-GFP-Rta mutant plasmids were kindly provided by Dr. Tsuey-Ying
Hsu (Hsu et al., 2005). pcDNA3-HA-Rta full-length plasmid was
provided by Dr. Shih-Tung Liu (Chang et al., 2004).
Transfections and luciferase assay
293 T cells were maintained in DMEM (Cellgro, Mediatech;
Manassas, VA) supplemented with 10% fetal bovine serum (FBS;
Cellgro). Transient transfection were performed in 6-well plates with
Lipofectamine 2000 (Invitrogen; Carlsbad, CA) according to the
manufacturer's protocol, and 0.2 µg reporter plasmid, 0.1 µg Renilla
luciferase plasmid (pRL-TK [Promega]), and 1 µg expression plasmid
used unless otherwise noted. At 24 h after transfection, cells were
harvested for luciferase assays as described before (Hahn et al., 2005;
Ning et al., 2003, 2005a,b) with dual luciferase assay reagent
(Promega); relative light units were normalized to the activity of
Renilla luciferase and used as internal control. Representative data of
three experiments done in triplicate are shown.
In some experiments, cells were infected with Sendai virus (50 HA
units/ml; a gift from Dr. Mark Heise, University of North Carolina at
Chapel Hill) 16 h post-transfection. Eight hours after infection, cells
were collected for analysis.
Immunoblotting
The harvested cell pellets were separated into cytoplasmic extract
and nuclear fractions by the method described (Smirnova et al., 2000)
or lysedwith 0.5% CHAPS in 20 mMHEPES (pH 7.4), 10 mMKCl, 1 mM
MgCl2, and 1 mM dithiothreitol (all Sigma-Aldrich). The modiﬁed
Bradford method was used to quantify protein concentration in
supernatant ﬂuids. Cellular proteins and pre-stained molecular mass
markers were subjected to SDS-PAGE and transferred to nitrocellulose
membrane. Membranes were blocked with 5% nonfat milk in TBST;
incubated with antibodies to ubiquitin γ-tubulin, lamin, GFP, Flag or
HA (1:2000) for 2 h; washed with TBST and stained with peroxidase-
conjugated anti-rabbit or anti-mouse IgG (1:5000). Immunoreactivity
was visualized by enhanced chemiluminescence (ECL kit; Santa Cruz).
127G.L. Bentz et al. / Virology 402 (2010) 121–128Semi-quantitative RT-PCR
293 T cells were plated in 6-well plates at a density of 7.5×105 the
day before experiments. Cells were transfected with 2 μg of plasmids
expressing EBV Rta or empty vector pCMV. 14 h post-transfection,
cells were stimulated with 500 U/ml of Type I IFN (Biomedical Lab).
RNA was harvested 24 h post-transfection using the Qiagen RNeasy
Kit. Total RNA was reverse-transcribed with ABI PRISM RT kit. The
cDNA was ampliﬁed by PCR reaction with speciﬁc sense and anti-
sense primers for IRF3, IRF5, IRF7, and actin. PCR products were
fractionated on 0.8% agarose gels, stained with ethidium bromide, and
bands detected by UV.
Induction of Akata cells
Akata cells, an EBV latently infected cell line derived from Burkitt's
lymphoma, were maintained in RPMI (Cellgro) supplemented with
10% heat-inactivated FBS. For induction of lytic infection, 3.0×107
cells were collected and divided into three samples. Each sample was
plated at a density of 2×106 cells per ml of medium. F(AB')2 fragment
to human IgG (100 μg/ml; MP Biomedicals, LCC., Solon, OH) was used
to cross-link cell surface IgG (Gershburg et al., 2004; Takada and Ono,
1989; Zacny et al., 1999). Cells were incubated for 1 h at 37 °C with 5%
CO2with occasionalmixing, at which time cell densitywas adjusted to
1×106 cells per ml of medium. At 0, 24, and 48 h after reactivation,
cells were collected. Half of each sample was used for Western blot
analyses of expression of IRF3, IRF5, IRF7, Rta, and EA-D. GAPDH was
used as loading control. Total RNA was harvested from the remaining
half of the sample, and semi-quantitative RT-PCR performed. Samples
were separated on 2% agarose gels to examine RNA expression of IRF3,
IRF5, IRF7, IFN-β, and Rta. Densitometry was performed with relative
RNA or protein expression normalized to GAPDH expression. Data are
shown as fold change (relative to 0 h post-induction)±standard
deviation of experiments performed in triplicate.
In some experiments, Akata cells (induced and left uninduced)
were infected with Sendai virus (50 HA units/ml) 24 h after
reactivation. 24 h after infection, supernatant ﬂuids were collected
and used for plaque assays of Sendai virus replication.
Plaque Assays
Plaque assays were performed as previously described in LLC-MK2
cells (Touzelet et al., 2009). Brieﬂy, cells were grown to conﬂuence in
six-well plates. Samples were serially diluted in DMEM and left to
absorb for 1 h at 37 °C. Cells were washed and overlaid with 3 ml
DMEM with 1% agar (Bacto), 1.5 mg.ml BSA (Sigma), and 1.2 μg/ml
trypsin (Sigma). Five days later, agar was removed, cells were stained
with crystal violet, and plaques were counted. Data are shown as fold
change in plaque-forming units (PFU)/ml (relative to uninduced) ±
standard deviation of experiments performed in triplicate.
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